- Home
- AEON
AEON
AEON Biopharma Inc.
as 11-12-2025 2:39pm EST
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 10.6M | IPO Year: | N/A |
| Target Price: | $7.20 | AVG Volume (30 days): | 258.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.38 - $64.80 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest AEON Biopharma Inc. News
AEON Breaking Stock News: Dive into AEON Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing
GlobeNewswire
3 months ago
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
GlobeNewswire
6 months ago
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
GlobeNewswire
6 months ago
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
MT Newswires
7 months ago
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance
GlobeNewswire
7 months ago
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GlobeNewswire
7 months ago
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Compare AEON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AEON AEON Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.